Intravenous hexarelin increased GH in a small study of healthy men, with a peak around 30 minutes. The approximately 55-minute decay described in that paper concerns the GH response and should not be presented as hexarelin’s drug half-life.[1]
- This acute endocrine study does not establish chronic performance benefits or recovery schedules.
Inspection history
Clinical review: not reviewed by a qualified clinician.
· Independently inspected the listed passages; replaced or qualified inherited assertions. No qualified clinical review has occurred.
· Independent fresh reinspection for the deep-evidence pass: reopened every cited source at its passages via NCBI E-utilities / DailyMed / accessdata.fda.gov / govinfo.gov / Wayback Machine mirror, checked Europe PMC correction/retraction metadata where applicable, and confirmed the claim's wording against the primary text. Disposition: supported within the stated scope. No qualified clinical review.